BR112012022342A2 - anticorpos monoclonais dirigidos a cd52 - Google Patents

anticorpos monoclonais dirigidos a cd52

Info

Publication number
BR112012022342A2
BR112012022342A2 BR112012022342A BR112012022342A BR112012022342A2 BR 112012022342 A2 BR112012022342 A2 BR 112012022342A2 BR 112012022342 A BR112012022342 A BR 112012022342A BR 112012022342 A BR112012022342 A BR 112012022342A BR 112012022342 A2 BR112012022342 A2 BR 112012022342A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
targeted monoclonal
antibodies
canine
targeted
Prior art date
Application number
BR112012022342A
Other languages
English (en)
Inventor
Hansen Genevieve
Original Assignee
Vet Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vet Therapeutics Inc filed Critical Vet Therapeutics Inc
Publication of BR112012022342A2 publication Critical patent/BR112012022342A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

anticorpos monoclonais dirigidos a cd52. a invenção fornece anticorpos para antígenos caninos, felinos ou equinos, por exemplo, cd52 canino, e métodos para preparar e usar os anticorpos descritos.
BR112012022342A 2010-03-04 2011-03-03 anticorpos monoclonais dirigidos a cd52 BR112012022342A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31045010P 2010-03-04 2010-03-04
PCT/US2011/027094 WO2011109662A1 (en) 2010-03-04 2011-03-03 Monoclonal antibodies directed to cd52

Publications (1)

Publication Number Publication Date
BR112012022342A2 true BR112012022342A2 (pt) 2017-02-14

Family

ID=44531535

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022342A BR112012022342A2 (pt) 2010-03-04 2011-03-03 anticorpos monoclonais dirigidos a cd52

Country Status (7)

Country Link
US (2) US8652470B2 (pt)
EP (1) EP2542258A4 (pt)
JP (2) JP2013520999A (pt)
AU (2) AU2011223547B2 (pt)
BR (1) BR112012022342A2 (pt)
CA (1) CA2791866A1 (pt)
WO (1) WO2011109662A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
JP2013520999A (ja) 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ５２に対するモノクローナル抗体
BR112013028652A8 (pt) * 2011-05-06 2017-12-26 Nvip Pty Ltd Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos
WO2013063186A2 (en) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
MX357655B (es) 2011-11-15 2018-07-18 Walter & Eliza Hall Inst Medical Res Mediador soluble.
AU2013344807B2 (en) * 2012-11-15 2018-05-24 The Walter And Eliza Hall Institute Of Medical Research Soluble mediator
JP6493692B2 (ja) * 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
HUE041497T2 (hu) 2014-02-14 2019-05-28 Cellectis Immunsejteken és patológiás sejteken egyaránt jelen lévõ antigént célzó génmódosított sejtek immunterápia célra
RU2722562C2 (ru) 2014-09-30 2020-06-01 Интервет Интернэшнл Б.В. Антитела к pd-l1, связывающие pd-l1 собаки
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
CN116785434A (zh) * 2023-03-29 2023-09-22 暨南大学附属第一医院（广州华侨医院） 一种cd52+巨噬细胞作为骨关节炎治疗靶点的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JP3672306B2 (ja) * 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
US6573372B2 (en) * 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
WO2001049265A1 (en) 1999-12-30 2001-07-12 Dana-Farber Cancer Institute, Inc. Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
EP1461428B1 (en) * 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Method for producing hybrid antibodies
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP1485126A4 (en) * 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
EP1519959B1 (en) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
ATE482719T1 (de) * 2002-02-21 2010-10-15 Univ Duke Behandlungsverfahren unter verwendung von anti- cd22-antikörpern
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
EA010570B1 (ru) 2002-11-07 2008-10-30 Иммьюноджен, Инк. Антитело к cd33 и способы его применения
BRPI0416141B8 (pt) * 2003-11-01 2021-05-25 Biovation Ltd anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
EP2374815A1 (en) * 2004-05-28 2011-10-12 IDEXX Laboratories, Inc. Canine CD20 compositions
CA2577329A1 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2007024249A2 (en) * 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2006126068A2 (en) * 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
US8217147B2 (en) * 2005-08-10 2012-07-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
NZ591252A (en) * 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
JP2013520999A (ja) 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ５２に対するモノクローナル抗体
EP2542262A4 (en) 2010-03-04 2014-02-26 Vet Therapeutics Inc MONOCLONAL ANTIBODIES DIRECTED AGAINST CD20

Also Published As

Publication number Publication date
AU2011223547A1 (en) 2012-11-01
EP2542258A1 (en) 2013-01-09
JP2013520999A (ja) 2013-06-10
JP2017000142A (ja) 2017-01-05
CA2791866A1 (en) 2011-09-09
US20110217304A1 (en) 2011-09-08
EP2542258A4 (en) 2013-08-21
US8652470B2 (en) 2014-02-18
US20140341912A1 (en) 2014-11-20
AU2016210744A1 (en) 2016-08-25
WO2011109662A1 (en) 2011-09-09
AU2011223547B2 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
BR112012022342A2 (pt) anticorpos monoclonais dirigidos a cd52
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
CR20120371A (es) Antagonistas de pcsk9
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MA34091B1 (fr) Anticorps anti-cd40
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
EA201490454A1 (ru) Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ
EA201990959A1 (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
CO7250445A2 (es) Proteínas de unión a antígeno st2
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CY1119154T1 (el) Anti-vla-4 αντισωματα
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
ECSP14020644A (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
MX342034B (es) Proteinas monovalentes que se unen a antigenos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.